Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JCR to Begin Multinational Clinical Trials for LSDs in FY2011: Mr Ashida
November 29, 2010
- Otsuka Wins Abilify Patent Lawsuit in the US
November 29, 2010
- JCR Boosts Production Capacity for Epoetin Biosimilar
November 29, 2010
- Tsumura: Sales, Profits Rise Due to Growth in Ethical Kampo Medicines
November 29, 2010
- Korosho to Ask Drug Firms to Develop 29 More Unapproved Drugs/Indications
November 29, 2010
- JPMA to Organize “Asian Liaison Conference”
November 29, 2010
- End of R&D Tax Break to Result in Tax Increases for Pharma Industry: PMDA
November 29, 2010
- BioWa Licenses POTELLIGENT Technology to Agensys
November 29, 2010
- Otsuka Applies for Mucosta Eye Drop for Dry Eye
November 29, 2010
- Rohto: Record-High Profits despite Flat Sales
November 29, 2010
- Otsuka Applies for Levocarnitine Based on Published Evidence
November 29, 2010
- GSK to Launch Switch OTC Steroidal Agent
November 29, 2010
- Nippon Kayaku Applies for LCH for Exal Based on Data from Public Domain
November 29, 2010
- Oral Ketotifen Products Should Remain in Class 1: JPA
November 29, 2010
- Bristol-Myers Required to Develop Largest Number of Unapproved Drugs/Indications
November 29, 2010
- 64 Amaryl Generics from 28 Companies Listed
November 29, 2010
- Better Understanding of Etiology Essential to Develop Effective Anti-AD Drugs: Dr Iwai of Astellas
November 29, 2010
- New Premiums for Dispensing Generics Boost Sales of Top-4 Generic Makers
November 29, 2010
- Indacaterol as Effective as Tiotropium: Novartis
November 29, 2010
- Takara Bio: Sales Down 2.9%, Instrument Business in Slump
November 29, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…